The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells

Experimental Cell Research

Volumn 315, Issue 14, 2009, Pages 2343-2357

  Zhan, Yi ^a   Counelis, George J ^a   O'Rourke, Donald M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell cycle; EGFRvIII; Human glioblastoma cells; SHP 2; Transformation

Indexed keywords

ACTIN; AGAR; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; TYROSINE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE EMBRYO; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS FIBER; TUMOR CELL;

MUS MUSCULUS;

EID: 67649224094     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.05.001     Document Type: Article

References (55)

1. Laskin J.J., and Sandler A.B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 30 (2004) 1-17
2. Nagane M., Lin H., Cavenee W.K., and Huang H.J. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 162 (2001) S17-S21 Suppl
3. Jungbluth A.A., Stockert E., Huang H.J., Collins V.P., Coplan K., Iversen K., Kolb D., Johns T.J., Scott A.M., Gullick W.J., Ritter G., Cohen L., Scanlan M.J., Cavenee W.K., and Old L.J. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 639-644
4. Wikstrand C.J., McLendon R.E., Friedman A.H., and Bigner D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 57 (1997) 4130-4140
5. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., and Reist C.J. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55 (1995) 3140-3148
6. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn, P.W. Zoltick, J.A. Biegel, R.L. Hayes, A.J. Wong, Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res. 55 (1995) 5536-5539.
7. Moscatello D.K., Montgomery R.B., Sundareshan P., McDanel H., Wong M.Y., and Wong A.J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13 (1996) 85-96
8. Nagane M., Levitzki A., Gazit A., Cavenee W.K., and Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5724-5729
9. Han Y., Caday C.G., Nanda A., Cavenee W.K., and Huang H.J. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 56 (1996) 3859-3861
10. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110 (2002) 669-672
11. Hunter T. Signaling-2000 and beyond. Cell 100 (2000) 113-127
12. Pawson T., Gish G.D., and Nash P. SH2 domains, interaction modules and cellular wiring. Trends Cell. Biol. 11 (2001) 504-511
13. Freeman R.M.Jr., Plutzky J., and Neel B.G. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 11239-11243
14. Ahmad S., Banville D., Zhao Z., Fischer E.H., and Shen S.H. A widely expressed human protein-tyrosine phosphatase containing Src homology 2 domains. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 2197-2201
15. Feng G.S., Hui C.C., and Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science 259 (1993) 1607-1611
16. Lechleider R.J., Freeman R.M.Jr., and Neel B.G. Tyrosyl phosphorylation and growth factor receptor association of the human corkscrew homologue, SH-PTP2. J. Biol. Chem. 268 (1993) 13434-13438
17. Yamauchi K., Milarski K.L., Saltiel A.R., and Pessin J.E. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 664-668
18. Qu C.K. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell. Res. 10 (2000) 279-288
19. Milarski K.L., and Saltiel A.R. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J. Biol. Chem. 269 (1994) 21239-21243
20. Bennett A.M., Hausdorff S.F., O'Reilly A.M., Freeman R.M., and Neel B.G. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell. Biol. 16 (1996) 1189-1202
21. Shi Z.Q., Lu W., and Feng G.S. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273 (1998) 4904-4908
22. Lu X., Qu C.K., Shi Z.Q., and Feng G.S. Downregulation of platelet-derived growth factor receptor-beta in Shp-2 mutant fibroblast cell lines. Oncogene 17 (1998) 441-448
23. Yu D.H., Qu C.K., Henegariu O., Lu X., and Feng G.S. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem. 273 (1998) 21125-21131
24. Manes S., Mira E., Gomez-Mouton C., Zhao Z.J., Lacalle R.A., and Martinez A.C. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cell. Biol. 19 (1999) 3125-3135
25. Hakak Y., Hsu Y.S., and Martin G.S. Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene 19 (2000) 3164-3171
26. Chen J., Yu W.M., Daino H., Broxmeyer H.E., Druker B.J., and Qu C.K. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109 (2007) 778-785
27. Loh M.L., Vattikuti S., Schubbert S., Reynolds M.G., Carlson E., Lieuw K.H., Cheng J.W., Lee C.M., Stokoe D., Bonifas J.M., Curtiss N.P., Gotlib J., Meshinchi S., Le Beau M.M., Emanuel P.D., and Shannon K.M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103 (2004) 2325-2331
28. Tartaglia M., Martinelli S., Iavarone I., Cazzaniga G., Spinelli M., Giarin E., Petrangeli V., Carta C., Masetti R., Arico M., Locatelli F., Basso G., Sorcini M., Pession A., and Biondi A. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br. J. Haematol. 129 (2005) 333-339
29. Ostman A., Hellberg C., and Bohmer F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6 (2006) 307-320
30. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., Richards W.G., Du J., Girard L., Minna J.D., Loh M.L., Fisher D.E., Velculescu V.E., Vogelstein B., Meyerson M., Sellers W.R., and Neel B.G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64 (2004) 8816-8820
31. Zhou X., Coad J., Ducatman B., and Agazie Y.M. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 53 (2008) 389-402
32. Zhan Y., and O'Rourke D.M. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res. 64 (2004) 8292-8298
33. Boockvar J.A., Kapitonov D., Kapoor G., Schouten J., Counelis G.J., Bogler O., Snyder E.Y., McIntosh T.K., and O'Rourke D.M. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol. Cell. Neurosci. 24 (2003) 1116-1130
34. Higashi H., Nakaya A., Tsutsumi R., Yokoyama K., Fujii Y., Ishikawa S., Higuchi M., Takahashi A., Kurashima Y., Teishikata Y., Tanaka S., Azuma T., and Hatakeyama M. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. J. Biol. Chem. 279 (2004) 17205-17216
35. Chen L., Sung S.S., Yip M.L., Lawrence H.R., Ren Y., Guida W.C., Sebti S.M., Lawrence N.J., and Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 70 (2006) 562-570
36. O'Rourke D.M., Nute E.J., Davis J.G., Wu C., Lee A., Murali R., Zhang H.T., Qian X., Kao C.C., and Greene M.I. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene 16 (1998) 1197-1207
37. Kapoor G.S., and O'Rourke D.M. Mitogenic signaling cascades in glial tumors. Neurosurgery 52 (2003) 1425-1434 discussion 1434-1435
38. Kapoor G.S., Zhan Y., Johnson G.R., and O'Rourke D.M. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol. Cell. Biol. 24 (2004) 823-836
39. Wu C.J., O'Rourke D.M., Feng G.S., Johnson G.R., Wang Q., and Greene M.I. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 20 (2001) 6018-6025
40. Lu W., Gong D., Bar-Sagi D., and Cole P.A. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell. 8 (2001) 759-769
41. Laird A.D., and Shalloway D. Oncoprotein signalling and mitosis. Cell Signal. 9 (1997) 249-255
42. Dance M., Montagner A., Salles J.P., Yart A., and Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 20 (2008) 453-459
43. Chan G., Kalaitzidis D., and Neel B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27 (2008) 179-192
44. Kuan C.T., Wikstrand C.J., and Bigner D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8 (2001) 83-96
45. Pedersen M.W., Tkach V., Pedersen N., Berezin V., and Poulsen H.S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int. J. Cancer 108 (2004) 643-653
46. Wikstrand C.J., Cole V.R., Crotty L.E., Sampson J.H., and Bigner D.D. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol. Immunother. 50 (2002) 639-652
47. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., and Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7727-7731
48. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., and Bigner D.D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6 (1995) 1251-1259
49. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., and Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005) 2012-2024
50. Klingler-Hoffmann M., Fodero-Tavoletti M.T., Mishima K., Narita Y., Cavenee W.K., Furnari F.B., Huang H.J., and Tiganis T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. J. Biol. Chem. 276 (2001) 46313-46318
51. Yuan L., Yu W.M., and Qu C.K. DNA damage-induced G2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J. Biol. Chem. 278 (2003) 42812-42820
52. Lorimer I.A., Wikstrand C.J., Batra S.K., Bigner D.D., and Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer. Res. 1 (1995) 859-864
53. Fan Q.W., and Weiss W.A. RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 24 (2005) 829-837
54. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73 (2004) 39-85
55. Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., and Shoelson S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92 (1998) 441-450